Bufalin has been shown to be effective against a variety of
cancer cells, but its role in
lung cancer has never been studied in an animal model. In this study, we evaluated
bufalin effects in a human
lung cancer cell line NCI-H460 both in vitro and in vivo.
Bufalin caused significant cytotoxicity in NCI-H460 cells at a concentration as low as 1 μM.
DNA condensation was observed in
bufalin-treated cells in a dose-dependent manner. Mitochondrial membrane potential (ΔΨm ) was reduced and
reactive oxygen species (ROS) were increased in
bufalin-treated NCI-H460 cells. Levels of several proapoptotic
proteins such as Fas,
Fas-ligand,
cytochrome c, apoptosis
protease activating factor-1,
endonuclease G,
caspase-3 and
caspase-9 were increased after
bufalin treatment. At the same time, anti-apoptotic
B-cell lymphoma 2
protein levels were reduced.
Bufalin decreased
glucose regulated protein-78 gene expression but increased growth arrest- and DNA damage-inducible 153 gene expression.
Bufalin injected intraperitoneally in a dose-dependent manner reduced
tumor size in BALB/C nu/nu mice implanted with NCI-H460 cells.
Bufalin injection did not produce significant
drug-related toxicity in experimental animals except at a high dose (0.4 mg kg-1 ). In conclusion, low concentrations of
bufalin can induce apoptosis in the human
lung cancer cell line NCI-H460 in vitro.
Bufalin also reduced
tumor size in mice injected with NCI-H460 cells without significant
drug-related toxicity. These results indicate that
bufalin may have potential to be developed as an agent for treating human
non-small cell lung cancer. © 2016 Wiley Periodicals, Inc. Environ Toxicol 32: 1305-1317, 2017.